Efficacy, Safety, Pharmacokinetics, and Immunogenicity of DRL-Trastuzumab Versus Herceptin in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: A Randomized Controlled Trial ...
Organ preservation has become an attractive alternative to surgery (total mesorectal excision [TME]) among patients with rectal cancer after neoadjuvant therapy who achieve a clinical complete ...
Integration of Telemedicine Consultation Into a Tertiary Radiation Oncology Department: Predictors of Use, Treatment Yield, and Effects on Patient Population Using the scoping review methodology ...
UGT1A1 Testing for the Risk of Nanoliposomal Irinotecan–Related Toxicity Phase III trials that randomly assign patients to a control treatment (C), an experimental treatment (A), or a combination ...
Tumor-Informed Circulating Tumor DNA for Minimal Residual Disease Detection in the Management of Colorectal Cancer The median follow-up for censored patients was 7.9 years. According to NCCN risk ...
Between July 1997 and December 2019, Hispanic women, living in the United States or in Latin America, enrolled in the Clinical Cancer Genomics Community Research Network registry were prospectively ...
In the article that accompanies this editorial, Wu et al 36 observed that residential exposure to fine particulate matter was associated with higher breast cancer incidence using prospective data from ...
Cost-Effectiveness of Total Neoadjuvant Therapy With Selective Nonoperative Management for Locally Advanced Rectal Cancer: Analysis of Data From the Organ Preservation for Rectal Adenocarcinoma Trial ...
A total of 23 studies from 11 registries in eight countries spanning Europe, North America, and Oceania were identified and included in the review. Most studies were retrospective in nature and ...
Comprehensive Genomic Assessment of Advanced-Stage GI Stromal Tumors Using the Japanese National Center for Cancer Genomics and Advanced Therapeutics Database We analyzed the genomic and immune ...
KRASG12D-Mutated Metastatic Colorectal Cancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted Alteration MEREDITH identified a broader range of treatment options ...
View all available purchase options and get full access to this article. Authors retain all rights in any data supplements associated with their articles. The ideas and opinions expressed in this Data ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback